Real World Efficacy of Pembrolizumab of as a 1st Line Treatment in Metastatic Non-Small Cell Lung Cancer with PD-L1 High Expression

被引：0

作者：

Kasahara, K. ^{[1
]}

Sone, T. ^{[1
]}

Nishi, K. ^{[2
]}

Shibata, K. ^{[3
]}

Araya, T. ^{[4
]}

Shirasaki, H. ^{[5
]}

Yoneda, T. ^{[6
]}

Kase, K. ^{[7
]}

Nishikawa, S. ^{[1
]}

Kimura, H. ^{[1
]}

Tambo, Y. ^{[1
]}

机构：

[1] Kanazawa Univ, Resp Med, Kanazawa, Ishikawa, Japan

[2] Ishikawa Prefectural Cent Hosp, Resp Med, Kanazawa, Ishikawa, Japan

[3] Kouseiren Takaoka Hosp, Med Oncol, Takaoka, Toyama, Japan

[4] Natl Hosp Org Kanazawa Med Ctr, Resp Med, Kanazawa, Ishikawa, Japan

[5] Fukui Ken Saiseikai Hosp, Resp Med, Fukui, Japan

[6] Komatsu Municipal Hosp, Resp Med, Komatsu, Japan

[7] Keiju Med Ctr, Resp Med, Nanao, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期

关键词：

Pembrolizumab; 1st line treatment; PD-L1 high expression;

D O I：

10.1016/j.jtho.2019.08.953

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.04-50

引用

页码：S460 / S460

页数：1

共 50 条

[41] Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
Zeng, Tian
Qin, Qin
Bian, Zhiheng
Li, Jianjun
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2019, 47 (01) : 4194 - 4201
[42] Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab
Svaton, Martin
Knetki-Wroblewska, Magdalena
Tabor, Sylwia
Domecky, Petr
Venclicek, Ondrej
Krejci, Jana
Drosslerova, Marie
Hrnciarik, Michal
Hricisak, Daniel
Bejckova, Alzbeta
Fischer, Ondrej
Vitkova, Martina
Krzakowski, Maciej
IN VIVO, 2024, 38 (05): : 2434 - 2440
[43] Challenges of PD-L1 testing in non-small cell lung cancer and beyond
Wang, Minyu
Wang, Sen
Trapani, Joseph A.
Neeson, Paul J.
JOURNAL OF THORACIC DISEASE, 2020, 12 (08) : 4541 - 4548
[44] Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis
Zhang, Binbin
Liu, Yi
Zhou, Sijing
Jiang, Huihui
Zhu, Ke
Wang, Ran
INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 80
[45] Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report
Alfonso Fiorelli
Fabio Perrotta
Mariano Mollica
Mario Santini
Fabiana Vitiello
Marina Gilli
Cecilia Calabrese
Andrea Bianco
Journal of Cardiothoracic Surgery, 14
[46] Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report
Fiorelli, Alfonso
Perrotta, Fabio
Mollica, Mariano
Santini, Mario
Vitiello, Fabiana
Gilli, Marina
Calabrese, Cecilia
Bianco, Andrea
JOURNAL OF CARDIOTHORACIC SURGERY, 2019, 14 (1)
[47] PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)
Jiang, Liyan
Su, Xinying
Zhang, Tianwei
Yin, Xiaolu
Zhang, Meizhuo
Fu, Haihua
Han, Hulin
Sun, Yun
Dong, Lili
Qian, Jialin
Xu, Yanhua
Fu, Xuan
Gavine, Paul R.
Zhou, Yanbin
Tian, Kun
Huang, Jiaqi
Shen, Dong
Jiang, Haiyi
Yao, Yihong
Han, Baohui
Gu, Yi
ONCOTARGET, 2017, 8 (16) : 26845 - 26857
[48] Cost-effectiveness analysis of PD-L1 testing associated with pembrolizumab for first-line treatment of advanced non-small cell lung cancer in China
Wu, Yao
Tao, Libo
Liu, Chang
Wang, Fangxu
Sun, Shuang
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2025, : 737 - 746
[49] Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Hersom, Maria
Jorgensen, Jan T.
THERAPEUTIC DRUG MONITORING, 2018, 40 (01) : 9 - 16
[50] Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors
Malhotra, Jyoti
Huang, Amy
Amini, Arya
Lee, Percy
CANCERS, 2024, 16 (21)

← 1 2 3 4 5 →